Summit Therapeutics Stock Forecast, Price & News

Summit Therapeutics (NASDAQ:SMMT) Frequently Asked Questions

Is Summit Therapeutics a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Summit Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SMMT, but not buy additional shares or sell existing shares.
View analyst ratings for Summit Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Summit Therapeutics?

Wall Street analysts have given Summit Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Summit Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Summit Therapeutics?

Summit Therapeutics saw a drop in short interest in August. As of August 13th, there was short interest totaling 688,600 shares, a drop of 18.6% from the July 29th total of 845,900 shares. Based on an average trading volume of 219,100 shares, the short-interest ratio is currently 3.1 days. Approximately 2.8% of the company's stock are sold short.
View Summit Therapeutics' Short Interest.

When is Summit Therapeutics' next earnings date?

Summit Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Summit Therapeutics.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) announced its quarterly earnings results on Wednesday, August, 11th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.09. Summit Therapeutics had a negative net margin of 350.72% and a negative trailing twelve-month return on equity of 96.34%.
View Summit Therapeutics' earnings history.

How has Summit Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Summit Therapeutics' stock was trading at $1.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SMMT stock has increased by 163.5% and is now trading at $4.98.
View which stocks have been most impacted by COVID-19.

Who are Summit Therapeutics' key executives?

Summit Therapeutics' management team includes the following people:

• Mr. Robert W. Duggan, Exec. Chairman & CEO (Age 77)
• Mr. Michael Paul Donaldson, Chief Financial Officer (Age 44, Pay $296.2k)
• Dr. Mahkam Zanganeh M.B.A., D.D.S., MBA, COO & Director (Age 51, Pay $459.38k)
• Prof. Dame Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 71)
• Dr. David Jonathan Powell, Chief Scientific Officer (Age 51)
• Ms. Michelle Avery, Director of Investor Relations
• Mr. Dave Gancarz, Head of Investor Relations & Corp. Strategy
• Ms. Christine Armstrong, VP of Marketing?
• Mr. Campbell Hair, Head of HR?
• Dr. Jonathon Tinsley, Chief Scientific Officer of DMD (Age 62)

Who are some of Summit Therapeutics' key competitors?

Some companies that are related to Summit Therapeutics include Organogenesis (ORGO), Trillium Therapeutics (TRIL), NGM Biopharmaceuticals (NGM), MorphoSys (MOR), Amneal Pharmaceuticals (AMRX), Global Blood Therapeutics (GBT), Centessa Pharmaceuticals (CNTA), IVERIC bio (ISEE), Prelude Therapeutics (PRLD), Dicerna Pharmaceuticals (DRNA), Kadmon (KDMN), uniQure (QURE), Day One Biopharmaceuticals (DAWN), Travere Therapeutics (TVTX) and PureTech Health (PRTC).
View all of SMMT's competitors.

What other stocks do shareholders of Summit Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), (CATB), Gilead Sciences (GILD), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Ford Motor (F) and Martin Midstream Partners (MMLP).

When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.13%), Vanguard Group Inc. (0.90%), Baillie Gifford & Co. (0.45%), State Street Corp (0.26%), Geode Capital Management LLC (0.23%) and Morgan Stanley (0.22%). Company insiders that own Summit Therapeutics stock include David Jonathan Powell, Maky Zanganeh and Robert W Duggan.
View institutional ownership trends for Summit Therapeutics.

Which institutional investors are selling Summit Therapeutics stock?

SMMT stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Bank of America Corp DE, Citigroup Inc., and JPMorgan Chase & Co..
View insider buying and selling activity for Summit Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Summit Therapeutics stock?

SMMT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., State Street Corp, Geode Capital Management LLC, Baillie Gifford & Co., Renaissance Technologies LLC, Charles Schwab Investment Management Inc., and Nuveen Asset Management LLC. Company insiders that have bought Summit Therapeutics stock in the last two years include Maky Zanganeh, and Robert W Duggan.
View insider buying and selling activity for Summit Therapeutics or or view top insider-buying stocks.

How do I buy shares of Summit Therapeutics?

Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Summit Therapeutics' stock price today?

One share of SMMT stock can currently be purchased for approximately $4.98.

How much money does Summit Therapeutics make?

Summit Therapeutics has a market capitalization of $484.96 million and generates $20.17 million in revenue each year. The company earns $-52,700,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

How many employees does Summit Therapeutics have?

Summit Therapeutics employs 80 workers across the globe.

What is Summit Therapeutics' official website?

The official website for Summit Therapeutics is www.summitplc.com.

Where are Summit Therapeutics' headquarters?

Summit Therapeutics is headquartered at 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via email at [email protected].